CAMBRIDGE NUTRITIONAL SCIENCES PLC — Regulatory Filings 2018

May 21, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6474O

Omega Diagnostics Group PLC

21 May 2018

Omega Diagnostics Group PLC

("Omega" or "the Company" or the "Group")

VISITECT® CD4 development update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update with its VISITECT® CD4 development programme.

Further to the announcement on 10 April 2018, the Company recently held a design review meeting for its VISITECT® CD4 test for identifying advanced HIV disease*. The Company confirms that results from feasibility testing show acceptable performance against design goals and accordingly, the Company has progressed into a formal optimisation phase within its design control programme.

Colin King, CEO of Omega commented: "I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications. This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market. I look forward to making further announcements as we bring this product to market."

* defined as those patients with lower than 200 CD4+ T cells per microlitre of blood

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC	Tel: 01259 763 030
Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: 020 7220 0500
Geoff Nash/James Thompson (Corporate Finance)
Camille Gochez/ Abigail Wayne (Corporate Broking)
Walbrook PR Limited	Tel: 020 7933 8780 or [email protected]
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCURSKRWRAVURR